Pharmaceuticals
HKeyBio Debuts HKEY-ExE™ 1.0 to Address Preclinical Bottlenecks in EoE and EgE Drug Development
The EoE-centered framework supports disease modeling, multidimensional efficacy endpoints, type 2 biomarker analysis, and cross-indication translational research BOSTON and SUZHOU, China, June 24, 2026 /PRNewswire/ -- HKeyBio, a preclinical contract research organization focused on autoimmune an...
2026-06-24 21:18
614
HKeyBio Launches NHP Fast-Tox Program for Accelerating Non-GLP NHP Safety Risk Screening
The program supports early tolerability assessment, PK/TK-linked safety evaluation, immune-related risk screening, and pre-GLP dose design for biologics and immunomodulatory drug programs BOSTON and SUZHOU, China, June 24, 2026 /PRNewswire/ -- HKeyBio, a preclinical CRO focused on autoimmune and...
2026-06-24 20:36
560
WuXi Biologics' 25th Drug Substance Facility Completes First GMP Production, Manufacturing Process Execution with Zero Deviations
SHANGHAI, June 24, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG17 drug substance facility located at the Shanghai Fengxian site has successfully completed its first GMP production camp...
2026-06-24 14:39
701
Finetech Debuts Fully Automatic Liquid Capsule Filling Machine at CPhI China 2026 in Shanghai
System delivers filling volume accuracy within ±2–3%, output of 15,600 capsules per hour, and in-line rejection rates below 0.2%, addressing critical dosing consistency requirements for pharmaceutical and nutraceutical manufacturers SHANGHAI, June 24, 2026 /PRNewswire/ -- Finetech Pharmaceutical ...
2026-06-24 13:57
565
Abbisko Therapeutics Deepens R&D Collaboration with Lilly
SHANGHAI, June 23, 2026 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced that it has entered into a strategic research collaboration and license agreement with Eli Lilly and Company ("Lilly"), a leading global pharmaceutical co...
2026-06-24 09:00
560
Mabwell Receives IND Clearance from NMPA for LILRB4/CD3-targeting TCE Bispecific Antibody 6MW5311
SHANGHAI, June 23, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the National Medical Products Administration (NMPA) of China has cleared the clinical trial application for its innovative L...
2026-06-24 08:00
681
Haisco Enters into Exclusive License Agreement with Nuvectis for Two Drug Candidates in Oncology and Complement Indications
BEIJING, June 23, 2026 /PRNewswire/ -- On June 23, 2026 (Beijing time), Haisco Pharmaceutical Group Co., Ltd. (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement withNuvectis, a U.S. biotechnology company. Under the agreement, Haisco has granted Nuvectis the ...
2026-06-23 21:17
829
CARsgen Announces Approval of Satri-cel, the World's First CAR T-Cell Therapy Product for Solid Tumors
SHANGHAI, June 22, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that as informed by the National Medical Products Administration ("NMPA") today, the New Drug Application ("NDA") of sat...
2026-06-22 19:20
856
Piramal Pharma Solutions Highlights Strong Performance Across More Than 200 Customer Audits
* Piramal Pharma Solutions completed more than 200 customer audits and received over 70 approvals from regulatory agencies across its global network over the past year, with strong overall outcomes. * This milestone reflects the Company's long-range quality strategy focused on sustained compl...
2026-06-22 16:57
740
Innogen Pharmaceutical Group Highlights China-Originated Innovation and Global Development Strategy at DIA Global Annual Meeting 2026 China Town Hall
From original GLP-1 science to international clinical development, Innogen shares its "from 0 to 1" innovation journey in metabolic diseases PHILADELPHIA, June 22, 2026 /PRNewswire/ -- During the DIA Global Annual Meeting 2026 held in Philadelphia, the China Town Hall session was successfully co...
2026-06-22 16:39
548
Insilico Medicine And SK Biopharmaceuticals Achieved AI-powered Drug Discovery Collaboration Worth Up to 2.5 Billion for Neuroimmune Disorders
CAMBRIDGE, Mass., June 22, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and SK Biopharmaceuticals, a Korean-based company leads the way in biotech innovation with groundbreaking drug research,...
2026-06-22 12:37
809
Mabwell Presents Clinical Results of Nectin-4-Targeting ADC 9MW2821 at 2026 ESMO Gynaecological Cancers Congress
SHANGHAI, June 18, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, presented two latest clinical study results of its independently developed Nectin-4-targeting ADC 9MW2821 (Bulumtatug Fuvedotin, BFv) in c...
2026-06-18 23:00
2503
WuXi Biologics' Suzhou Biosafety Testing Center Received Fourth EMA GMP Certification, Enabling 19 Commercial Products for the European Market
SUZHOU, China, June 18, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its Biosafety Testing Center in Suzhou has successfully passed a Good Manufacturing Practice (GMP) inspection by the Europe...
2026-06-18 12:57
3633
Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969, Achieving First Clinical Milestone in Collaboration with Hygtia Therapeutics
CAMBRIDGE, Mass. and HONG KONG, June 17, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced it has achieved the first clinical milestone in its co-development collaboration wit...
2026-06-17 21:00
3729
Ligufalimab (CD47)-Based Combination Achieves Deep Responses and Survival Benefit in Frontline AML: Phase II Results Presented in Oral Session at EHA 2026
HONG KONG, June 17, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that compelling results from its randomized, double-blind, placebo-controlled Phase II trial (AK117-206) of ligufalimab (AK117) were presented as an oral presentation at the 2026 European Hem...
2026-06-17 13:39
3455
2026 Tang Prize in Biopharmaceutical Science Awarded to Three Pioneers of Cellular Immunotherapy
Revolutionizing Treatments for Blood Cancers and Solid Tumors TAIPEI, June 16, 2026 /PRNewswire/ -- On June 16, the Tang Prize in Biopharmaceutical Science announced its 2026 laureates. The prize, whose laureates from previous cycles have subsequently received Nobel Prize honors, has drawn wide ...
2026-06-16 20:00
1900
DIMERIX EXCLUSIVELY LICENSES DMX-200 IN GREATER CHINA, SOUTH KOREA AND SOUTHEAST ASIA TO EVEREST MEDICINES
* Everest Medicines licenses exclusive rights to commercialise DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) in Greater China, South Korea and Southeast Asia * 500,000-1 million people are estimated to be living with FSGS in the territories[1] * Dimerix eligible to ...
2026-06-16 19:00
1895
Minghui Pharmaceutical Presents Compelling Phase I/II Results for MHB018A, a Novel Subcutaneous Anti-IGF-1R Antibody for Thyroid Eye Disease, in an Oral Presentation at ENDO 2026, the Endocrine Society's Annual Meeting
* MHB018A demonstrated outstanding clinical activity in both active and chronic thyroid eye disease * At 450 mg Q4W, MHB018A achieved a remarkable 81% proptosis response at Week 12 in active TED and a 76% proptosis response at Week 24 in chronic TED * MHB018A was generally well tolerated amo...
2026-06-16 09:00
3797
Harbour BioMed and BioMap Jointly Initiate MegaStream TechBio: A Leading Global Drug Development Platform Joins Forces with Premier Life Science Foundation Models to Set New Benchmarks for AI-Driven Complex Biologics R&D
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 15, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142.HK), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease areas, and BioMap, a global...
2026-06-15 20:10
3225
Bambusa Therapeutics Presents Positive Preliminary Multiple Ascending Dose Phase 1 Data for BBT002 at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026
- BBT002 is a next-generation, long-acting bispecific antibody targeting two clinically and commercially validated targets, IL-4Rα and IL-5 - - BBT002 demonstrated rapid, deep, and sustained biomarker effects through at least 8 weeks following multiple doses, consistent with the SAD data, with a ...
2026-06-15 19:00
2021
Week's Top Stories
Most Reposted
NOVVA Group acquires 120 MWp Philippines solar project, anchoring its AI-era power platform in Southeast Asia
[Picked up by 302 media titles]
2026-06-19 11:12
Affinidi and CardInfoLink Put the Missing Trust Layer for AI Agents into Production
[Picked up by 301 media titles]
2026-06-19 09:00
IPD and ABB Help Power Sustainable Operations at New Sydney Fish Market
[Picked up by 298 media titles]
2026-06-22 17:40
Carro enters Australia with CarPlace acquisition to bring better, transparent car buying and selling experience to Australians
[Picked up by 295 media titles]
2026-06-18 10:00
Most Read
Resilience Actions, a Re Sustainability Initiative, Launches ECOHUB.IN to Power India's Climate and Circular Economy Innovation Ecosystem
2026-06-19 19:33
6112
LEIFRAS Co., Ltd. Reports Financial Results for the First Quarter of Fiscal Year 2026
2026-06-19 04:00
5383
